Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) colonizes multiple body sites, and carriage is an important risk factor for MRSA infection. Successful decolonization reduces disease incidence; however, the optimal decolonization protocol is unclear. Decolonization protocols include diverse sets of treatments that target multiple body sites, and standard methods can not estimate the impact of site-specific components from such data. Here, we formulated a Bayesian coupled hidden Markov Model (CHMM) for MRSA colonization dynamics that estimates interactions between body sites and quantifies the contribution of each component on successful decolonization. Importantly, this now makes it possible 1) to predict the efficiency of decolonization for any combination of site-specific treatments, including combinations not included in the data, and 2) to assess the impact of enhancing site-specific clearance on the success of decolonization. We applied the model to longitudinal data from a randomized controlled trial (RCT) of MRSA decolonization, including chlorhexidine (CHG) body and mouthwash and nasal mupirocin. Our findings confirmed that nares are central to MRSA persistence and act as a predominant source of colonization for other body sites. We estimated the CHG mouthwash as the least effective component, such that the combined effect of clearance on other sites accounted for as much as 97% (90% credible interval 90%-99%) of the full decolonization. Hence, the omission of CHG mouthwash still yields a highly efficient decolonization regimen while facilitating adherence. Finally, we used our model to estimate the effectiveness of hypothetical treatment improvements in silico and showed that enhancing MRSA clearance at nares will achieve the largest gains. This study demonstrates the use of advanced probabilistic modeling to go beyond what is typically achieved by RCTs, enabling evidence-based decision-making to streamline clinical protocols.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01209234
Clinical Protocols
https://doi.org/10.1056/NEJMoa1716771
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used the data from https://doi.org/10.1056/NEJMoa1716771. This trial was approved by the institutional review board of the University of California Irvine. For more details about the data collection, please see the original article https://doi.org/10.1056/NEJMoa1716771
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
onur.poyraz{at}aalto.fi, msater{at}hsph.harvard.edu, lmiller{at}lundquist.org,jmckinnell{at}lundquist.org, sshuang{at}hs.uci.edu, ygrad{at}hsph.harvard.edu, pekka.marttinen{at}aalto.fi
Title is changed The methods section is updated Results are revised Model convergence is shown
Data Availability
The CLEAR (Changing Lives by Eradicating Antibiotic Resistance) Trial demonstrated that the use of a post-discharge decolonization protocol in MRSA carriers reduces infection and hospitalization rates; ClinicalTrial.gov number NCT01209234, see reference https://doi.org/10.1056/NEJMoa1716771 for informed consent and institutional review board approvals. The data used in the present article is available on request from the corresponding author Susan Huang of the https://doi.org/10.1056/NEJMoa1716771, a co-author of this study.
